WASHINGTON (AP) — In a significant step for families facing infertility, drug manufacturer EMD Serono has reached an agreement with the Trump administration to lower the cost of Gonal-f, a prominent fertility medication. President Trump announced this development and revealed new federal guidelines designed to promote employer-provided fertility coverage separately from major medical insurance plans, akin to offerings for dental and vision coverage.
This initiative is a part of Trump’s broader goal after issuing an executive order earlier this year to enhance accessibility and affordability of in vitro fertilization (IVF). Nevertheless, it does not meet his prior commitment made during his campaign to ensure free IVF treatment; this marks the third agreement made by the administration to reduce drug prices in recent weeks.
Gonal-f is commonly used in IVF treatment cycles, where patients utilize hormones to stimulate ovulation, which can be costly—often ranging from thousands to tens of thousands of dollars per cycle. As many individuals undergo multiple cycles to conceive successfully, any reduction in drug prices can significantly ease the financial burden.
The drug will soon be available at reduced rates through TrumpRx, a government platform for purchasing medications directly from manufacturers. Furthermore, the Food and Drug Administration (FDA) is collaborating with EMD Serono to expedite approval for another fertility drug, Pergoveris, currently available in Europe.
Following Trump’s executive order earlier this year, he had promised comprehensive insurance coverage for all costs associated with IVF, emphasizing the administration’s focus on increasing birth rates in America. Experts and advocates for fertility treatments view any progress in this area as a positive step.
Roger Shedlin, CEO of WIN, a fertility benefits company, stated that initiatives addressing drug pricing will have a meaningful impact on overall IVF costs. Similarly, families like that of Corinn O’Brien, who experienced the financial strain of IVF medications, expressed hope that these changes would significantly alleviate costs associated with fertility treatments, thereby aiding more families in achieving their dream of parenthood.
This initiative is a part of Trump’s broader goal after issuing an executive order earlier this year to enhance accessibility and affordability of in vitro fertilization (IVF). Nevertheless, it does not meet his prior commitment made during his campaign to ensure free IVF treatment; this marks the third agreement made by the administration to reduce drug prices in recent weeks.
Gonal-f is commonly used in IVF treatment cycles, where patients utilize hormones to stimulate ovulation, which can be costly—often ranging from thousands to tens of thousands of dollars per cycle. As many individuals undergo multiple cycles to conceive successfully, any reduction in drug prices can significantly ease the financial burden.
The drug will soon be available at reduced rates through TrumpRx, a government platform for purchasing medications directly from manufacturers. Furthermore, the Food and Drug Administration (FDA) is collaborating with EMD Serono to expedite approval for another fertility drug, Pergoveris, currently available in Europe.
Following Trump’s executive order earlier this year, he had promised comprehensive insurance coverage for all costs associated with IVF, emphasizing the administration’s focus on increasing birth rates in America. Experts and advocates for fertility treatments view any progress in this area as a positive step.
Roger Shedlin, CEO of WIN, a fertility benefits company, stated that initiatives addressing drug pricing will have a meaningful impact on overall IVF costs. Similarly, families like that of Corinn O’Brien, who experienced the financial strain of IVF medications, expressed hope that these changes would significantly alleviate costs associated with fertility treatments, thereby aiding more families in achieving their dream of parenthood.
